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IMMUNOBIOLOGY
Improved cellular and humoral immune responses in vivo following targeting
of HIV Gag to dendritic cells within human anti–human DEC205
monoclonal antibody
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Protein vaccines for T-cell immunity are
not being prioritized because of poor
immunogenicity. To overcome this
hurdle, proteins are being targeted to
maturing dendritic cells (DCs) within
monoclonal antibodies (mAbs) to DC
receptors. To extend the concept to
humans, we immunized human immuno-
globulin-expressing mice with human
DEC205 (hDEC205) extracellular do-
main. 3D6 and 3G9 mAbs were selected
for high-affinity binding to hDEC205. In
addition, CD11c promoter hDEC205
transgenic mice were generated, and
3G9 was selectively targeted to DCs in
these animals. When mAb heavy chain
was engineered to express HIV Gag p24,
the fusion mAb induced interferon-–
and interleukin-2–producing CD4
T cells in hDEC205 transgenic mice, if
polynocinic polycytidylic acid was coad-
ministered as an adjuvant. The T-cell
response was broad, recognizing at least
3 Gag peptides, and high titers of anti-
human immunoglobulin G antibody were
made. Anti-hDEC205 also improved the
cross-presentation of Gag to primed
CD8 T cells from HIV-infected individu-
als. In all tests, 3D6 and 3G9 targeting
greatly enhanced immunization relative
to nonbinding control mAb. These re-
sults provide preclinical evidence that
in vivo hDEC205 targeting increases the
efficiency with which proteins elicit spe-
cific immunity, setting the stage for
proof-of-concept studies of these new
protein vaccines in human subjects.
(Blood. 2010;116(19):3828-3838)
Introduction
Protein vaccines offer potential advantages with respect to ease and
low costs of production, and ability to be administered repeatedly.
Yet, protein vaccines characteristically suffer from poor immunoge-
nicity for the Th1 type of T cell–mediated immunity that should
help to resist global infectious diseases and cancers. The require-
ments for immunization are now better understood, particularly the
importance of antigen delivery to dendritic cells (DCs) to achieve
antigen presentation in vivo as well as DC maturation to differenti-
ate the cells to overcome their normal role in inducing tolerance by
different mechanisms.1-3 To meet these DC requirements, it is
logical to explore several receptors on DCs to improve antigen
uptake and presentation in vivo, as well as several adjuvants that
guide DC function.4,5
DEC205/CD205 is a member of the multilectin family of
C-type lectins expressed by mammalian cells.6 This family,
which include the mannose receptor, CD206, and the phospho-
lipase A2 receptor, have 8-10 external contiguous lectin do-
mains and mediate adsorptive endocytosis.7 Among leukocytes,
DEC205 is expressed at the highest levels by DCs within the
T-cell areas of lymphoid tissues, which are the sites for the
generation of immunity and tolerance. Although DCs are known
to express many potential receptors to enhance antigen uptake
and processing, DEC205 is currently the only receptor that has
been visualized on most DCs in the T-cell areas of human
lymphoid organs.8
Proteins can be targeted selectively to mouse DCs in vivo when
incorporated into a monoclonal antibody (mAb) specific for
DEC205.1,2 This targeting increases the efficiency of antigen
presentation on major histocompatibility complex (MHC) class I
and II molecules approximately 100-fold3,9-12 as well as strong and
protective T-cell immunity.10 With synthetic double-stranded RNA
as the only adjuvant, DEC205 targeting leads to Th1 immunity that
is also durable, lasting for several months in mice.13 The improved
cell-mediated immunity with polyriboinocinic polyribocytidylic
acid (poly IC) as an adjuvant is due to the high levels of type I
interferon (IFN) induced by this agonist through MDA5 and TLR3
pattern-recognition receptors. Specifically, the maturation of DCs
to become immunostimulatory requires their expression of type I
IFN receptors.14
To extend the concept of protein targeting to DCs to human
therapeutics, a series of human immunoglobulin G (IgG) mAbs to
human DEC205 (hDEC205) were produced from human Ig
transgenic mice that lack mouse Ig genes, but carry the human Ig
locus.15 While these mAbs also react with DEC205 in rhesus
macaques, the latter are expensive to explore the many variables
that are needed to move this vaccine strategy into proof-of-concept
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studies in humans. Therefore, we generated transgenic (Tg) mice
expressing the hDEC205 receptor on DCs. Below, we describe the
capacity of human anti–hDEC205-HIV Gag p24 fusion mAb to




Chinese hamster ovary (CHO) cells were cultured in Dulbecco modified
Eagle medium (DMEM; Invitrogen no. 11 995) 5%-10% fetal bovine serum
(FBS; Sigma-Aldrich) or 5% Ultra-Low IgG FBS supplemented with
2-mercaptoethanol, antibiotic-antimycotic, and nonessential amino acids
(all from GIBCO Invitrogen). Human monocyte-derived DCs (MoDCs)
were generated from normal blood monocytes purchased as buffy coats
from the New York Blood Center as previously described.16 Briefly, CD14
cells were isolated using anti-CD14 beads (Miltenyi Biotec) and cultured
6 days in RPMI 1640 (Invitrogen) with 5% human serum (Gemini
Bio-Products), interleukin-4 (IL-4; R&D Systems; 10 ng/mL), and
granulocyte-macrophage colony-stimulating factor (GM-CSF; Immunex;
100 IU/mL). To mature MoDCs, lipopolysaccharide (LPS; 100 ng/mL) was
added during the last 24 hours.
Expression of full-length human DEC205 and its external
region
A synthetic open reading frame (ORF) for full-length hDEC205 with a V5
epitope tag and stable CHO cells expressing hDEC205 (CHO/hDEC205
cells) were previously described.17 In brief, a full-length hDEC205 ORF
was amplified by polymerase chain reaction (PCR) from a human thymic
cDNA library (Clontech), followed by cloning and sequencing. To detect
the expression of full-length hDEC205 protein, the signal peptide was
replaced with a mouse IgG signal peptide and a V5 epitope tag (V5-tagged
hDEC205; GenBank accession no. AY682091). This synthetic hDEC205
ORF was inserted into a promoter of cytomegalovirus (pCMV) expression
vector, transfected, and stably expressed as CHO/hDEC205 cells. Similarly,
the full-length cDNA of mouse DEC205 (mDEC205; GenBank accession
no. AF395445) was cloned from C57Bl/6 spleen cDNAs and also inserted
into the pCMV for stable expression in CHO cells (CHO/mDEC205 cells).
A synthetic DNA for hDEC205 extracellular domain was generated
similarly, modified with V5-tagged mouse IgG signal peptide, and fused
in-frame with the human IgG1 (hIgG1) Fc domain amplified from human
genomic DNA. The V5.hDEC205/hIgG1Fc construct (GenBank accession
no. DQ407610) was inserted into the pCMV expression vector, transfected,
stably expressed as CHO/V5.hDEC205/hIgG1Fc cells, and the culture
supernatant was used to purify V5.hDEC205/hIgG1Fc fusion protein by
affinity to Protein A Sepharose (GE Healthcare) as described.18
Antibodies
Murinized NLDC145 mAb (mNLDC145, the original V regions from rat
anti-mDEC205 mAb modified to express mouse kappa and IgG1 constant
domains) and hybrid mAbs fused with antigens were previously described.1
The cDNAs of mouse lambda and IgG2b heavy chains of mouse anti-
hDEC205 mAb MG38.219 were cloned and expressed in 293T cells to
produce genetically cloned MG38.2 as previously described.20 Peroxidase-
conjugated anti-V5 antibody (Ab) was purchased from Invitrogen. Phyco-
erythrin (PE)–conjugated anti-human IgG was purchased from Jackson
ImmunoResearch Laboratories. Fluorescein isothiocyanate (FITC)–
anti-CD3, FITC-anti-B220, PerCP-anti-CD8, allophycocyanin (APC)–anti-
CD4, and APC-anti-CD11c were from BD Biosciences Pharmingen.
Generation of CD11c promoter-human DEC205 Tg mice
CD11c promoter-hDEC205 (CD11c-hDEC205) Tg mice were generated in
the C57BL/6 strain using standard microinjection techniques. Briefly,
hDEC205 cDNA was cloned into a synthetic CD11c promoter (GenBank
Accession no. DQ658851). The construct was linearized by digestion with
restriction enzymes AatII and AscI, purified, and injected into fertilized
pronuclei of C57BL/6 mice. Transgene-positive mice were mated with
C57BL/6. Six founders were established and confirmed for germ-line
transmission by PCR genotyping of tail DNA. The DEC205F 5-
TGGAAGAGACATGGAGAAACCT-3 and DEC205R 5-TCTCAGGC-
CAGTCCAGAAGTA-3 primers recognize conserved sequences in human
and mouse DEC205 genes, and distinguish amplicons of 165 and 293 bp
from the hDEC205 cDNA transgene and mouse DEC205 gene. hDEC205
Tg mice also mated with B10.BR(H2K). C57BL/6 or B10.BR mice were
purchased from Taconic Farms and mated with CD11c-hDEC205 Tg mice.
All animals were maintained under specific pathogen-free conditions and
used according to Rockefeller University institutional guidelines.
Immunization of human Ig Tg mice for human anti-hDEC205
mAbs
Human Ig Tg mice15 were immunized with 5-25 g of purified V5.hDEC205/
hIgG1Fc protein using either complete/incomplete Freund or RIBI mono-
phosphoryl lipid A (MPL) plus trehalose dicorynomycolate (TDM) as
adjuvants (Sigma-Aldrich). Mice with anti-hDEC205 titers were adminis-
tered with fusion-protein intravenously 3-4 days before harvesting spleen
cells for fusion with the murine myeloma cell line, P3  63Ag8.653.
Hybridoma supernatant was harvested and initially screened for human
IgG using a sandwich enzyme-linked immunosorbent assay (ELISA).
Human IgG-positive supernatants were then assayed by fluorescence-
activated cell sorting (FACS) for reactivity to CHO/hDEC205 cells and by
ELISA to V5.hDEC205/hIgG1Fc-coated plates. Human IgG anti-
hDEC205 hybridomas were subcloned and expanded before the purification
of human anti-hDEC205 mAbs by protein A column chromatography. The
3D6-p24 and 3G9-p24 hybrid mAb proteins were made as an in-frame
fusion of HIV Gag p24 cDNA at the C-terminus of the Ig heavy chains.
DNA for simian immunodeficiency virus (SIV) Gag p27 or Gag p41, that is,
amino acids 136-368 or 1-364 of SIV Gag p55 protein (from SIV mac 239)
were also cloned in-frame into the 3G9 heavy chain. Fusion mAbs were
expressed in 293T cells by transient transfection and purified by protein A
chromatography. 3G9 or control human IgG1 antibodies were conjugated
with Alexa 647 (Invitrogen), according to the manufacturer’s instructions.
Flow cytometry
Control and transfectant CHO cells or human MoDCs were suspended in
phosphate-buffered saline (PBS) containing 2% FBS (FACS buffer) and
distributed into round-bottom 96-well plates at 2  105 cells/well. Fifty
microliters of supernatant or purified anti-hDEC205 mAbs were added for
1 hour at 4°C. The cells were washed, incubated in 50 L of PE–anti-
human IgG (1:1000; Jackson ImmunoResearch Laboratories) in FACS
buffer at 4°C for 1 hour, and assayed on a BD FACSCalibur flow cytometer
at the Rockefeller University Flow Cytometry Resource Center.
Determination of affinity and rate constants of anti-hDEC205
mAbs by SPR
Binding affinity and kinetics of human anti-DEC205 mAbs were examined
by surface plasmon resonance (SPR) using a Biacore 2000 SPR instrument
(Biacore AB), according to the manufacturer’s guidelines. Purified human
DEC205 fusion (or control) protein was covalently linked to a Biacore CM5
sensor chip (carboxymethylated dextran covalently attached to a gold
surface; Biacore) using standard amine-coupling chemistry with an Amine
Coupling Kit provided by Biacore, according to its guidelines [Biacore,
comprising coupling reagents N-hydroxysuccinimide and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride]. Low levels of ligand
were immobilized to limit any effects of mass transport of analyte on kinetic
parameters, such that the RMAX observed was in the order of 200 RU.
Binding was measured by flowing the mAbs over the sensor chip in HEPES
buffer (HBS-N buffer, Biacore: HEPES [N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid] 0.24%, NaCl 0.88%, q.s. water, filtered/degassed, and
pre-equilibrated to room temperature with a 1:2000 dilution of Surfactant
P20) at 1.25-200nM and a flow rate of 35 L/min. Antigen-antibody
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association and dissociation kinetics were followed for approximately
300-600 seconds in each case. Corresponding controls were conducted
using an unrelated protein for “background” subtraction. A single injection
of 18mM NaOH for 17 seconds at 35 L/min was used as the regeneration
conditions throughout the study. Biacore’s kinetics wizard was used to
derive kinetic parameters from the concentration series of analyte diluted in
HBS-NP running buffer. Association and dissociation curves were fitted to a
1:1 Langmuir binding model using Biacore kinetics wizard software,
according to Biacore guidelines.
Western blot analysis and epitope mapping
Stably transfected CHO cells (above) and CHO cells expressing empty
vector (CHO/Neo cells) were lysed with RIPA lysis buffer (150mM NaCl,
50mM Tris-HCl, pH 8.0, 1% NP-40, 0.5% desoxycholate, 0.1% sodium
dodecyl sulfate [SDS]), including protease inhibitor cocktail (Roche
Applied Science). Cell lysates were mixed with glycerol (5%-10% final) for
loading and separated on 6% SDS-polyacrylamide gel electrophoresis
(PAGE), blotted onto Hybond-P polyvinylidine difluoride membrane (GE
Healthcare), incubated with 3G9 or NLDC145 mAb supernatants at 1:10,
detected by anti-human (for 3G9) or -rat (for NLDC145) IgG conjugated
with horseradish peroxidase (HRP) (Southern Biotech), and visualized with
enhanced chemiluminescence Plus reagents (GE Healthcare). To detect
V5-tagged protein by immunoblotting, HRP-conjugated anti-V5 Ab (1:
1000; Invitrogen) was used.
To map the subdomain containing the epitope bound by mAb 3G9, a
series of deletion constructs for hDEC205 extracellular domain were
generated with a FLAG-tag sequence, that is, CR/FN (GenBank accession
no. GU270871), CRD1/2 (accession no. GU270872), CRD3/4 (accession
no. GU270873), CRD5/6 (accession no. GU270874), CRD7/8 (accession
no. GU270875), and CRD9/10 (accession no. GU270876). Each construct
was cloned into the pCMV vector and transiently expressed into 293T cells
using Lipofectamine 2000 reagent (Invitrogen). Western blotting assays
were done on transfectant cell lysates on 12% SDS-PAGE using mAbs 3G9
and L5 (anti-FLAG) as described above.
Immunohistochemical analysis of DEC205 expression
Spleen and lymph nodes from CD11c-hDEC205 Tg mice were harvested
and frozen in Tissue-Tek OCT (optimal cutting temperature; Sakura Finetek
USA). Then, 10-m frozen sections were fixed 20 minutes in cold acetone,
blocked with 5% mouse serum in FACS buffer, and stained in humidified
chambers with purified human anti-hDEC205 mAbs, followed by mouse
antihuman IgG-PE (Jackson ImmunoResearch Laboratories) and anti-B220–
FITC (BD Biosciences). Sections were mounted in Aqua Poly/Mount
(Polysciences) and stored at 4°C until examination by deconvolution
microscopy (Olympus) and Zeiss LSM 510 laser scanning confocal
microscopy (Carl Zeiss MicroImaging) at the Rockefeller University
Bio-Imaging Resource Center.
In vivo targeting of 3G9 antibody
Briefly, 30 g of Alexa 647–labeled 3G9 or control human IgG1 mAbs
were injected intraperitoneally to wild-type or CD11c-hDEC205 Tg mice.
Then, 12 hours later, spleen cells were prepared with collagenase and
stained with FITC-conjugated anti-CD3, CD19, and DX-5 to exclude
lymphocytes plus anti-CD8, CD11c, and PDCA1 mAbs. Targeting of the
Alexa 647–labeled mAbs to subsets of DCs was analyzed with a BD LSRII
flow cytometer.
T-cell immunity after HIV and SIV Gag immunization of
CD11c-hDEC205 Tg mice
Mice were injected intraperitoneally with 5 or 10 g of 3G9-HIV Gag p24,
3D6-HIV Gag p24, 3G9-SIV Gag p41, 3G9-SIV Gag p27, or control
Ig-HIV Gag p24 fusion mAbs plus adjuvants. To detect responses with a
single immunization, the adjuvants were 50 g of poly IC and 25 g of
anti-CD40 mAb 1C10, while 50 g of poly IC alone was used 1 month
apart for prime-boost immunizations.13 Spleens were harvested 2 weeks
after the primary immunization or booster immunizations. SIV- or HIV-
specific T cells were analyzed by intracellular cytokine staining as
previously described.10,13 Spleen cells were stimulated with the entire HIV
Gag p24, SIV Gag p17, or SIV Gag p27 peptide mix, or HIV Gag p24
peptide pools or, as a negative control, nonrelated peptide mix of Yersinia
pestis LcrV21 at a concentration of 2 g/mL, or medium alone, in the
presence of a costimulatory anti-CD28 mAb (clone 37.51) for 6 hours.
Brefeldin A (10 g/mL) was added for the last 5 hours to accumulate
intracellular cytokines. Cells were then washed with FACS buffer, incu-
bated with Fc receptor-blocking mAb (2.4G2), and stained with Live/
Dead Fixable Aqua viability dye (Invitrogen), FITC- or Alexa Fluor
700–anti-CD3, PE-, or PerCP-anti-CD8, and PerCP Cy 5.5- or APC-anti-
CD4 for 20 minutes on ice. Following fixation and permeabilization using
Cytofix/Cytoperm solution (BD Biosciences Pharmingen), cytokines were
visualized with APC- or PE–anti-IFN- or anti-IL-2 antibodies for 15 min-
utes at room temperature for flow cytometry.
To assess the proliferation of primed T cells, bulk splenocytes were
labeled with carboxyfluorescein succinimidyl ester (CFSE; 107 cells/mL,
1M, 10 minutes, 37°C; Invitrogen) and cultured with anti-CD28 and either
HIV Gag p24, nonreactive peptide mix, or anti-CD3 (0.1 g/mL; positive
control) in 96-well, round-bottomed plates. After 3 days, samples were
restimulated 6 hours with p24 peptides and anti-CD28, adding Brefeldin A
(10 g/mL) for the last 5 hours. Cells were stained with PerCP-anti-CD3
and PE-anti-CD4 as described above, permeabilized, stained with APC-anti-
IFN- mAb for 15 minutes, and 40 000 CD3 events were acquired on BD
FACSCalibur.
Humoral immunity after HIV Gag p24 immunization of
CD11c-hDEC205 Tg mice
To assess B-cell immunity, groups of 3 CD11c-hDEC205 Tg mice were
injected intraperitoneally with 10 g of purified 3G9, 3D6, or isotype
control human IgG1 mAbs in the presence of 50 g of poly IC and 25 g of
anti-CD40 mAb 1C10. At day 25, mice were boosted intraperitoneally with
10 g of the respective antibodies without adjuvants. Serum samples were
collected at days 2, 5, 21, 31, 40, and 58. To measure specific antibody,
96-well ELISA plates (BD Falcon) were coated with 0.1 g of control
human IgG1 (the isotype of 3G9 and 3D6) in PBS per well overnight at 4°C.
After washing 3with PBS containing 0.1% Tween 20 (PBST), plates were
incubated with blocking solution (5% normal goat serum in PBST) for 1 hour at
37°C. Then, serial dilutions of serum samples in blocking solution were added
and incubated for 1 hour at 37°C. After washing, plates were incubated with
HRP-conjugated goat antibodies (Southern Biotech) against mouse total IgG,
IgG1, IgG2c, IgG2b, or IgG3 in blocking solution for 1 hour at 37°C. The levels
of mouse antihuman IgG1 antibodies were visualized by colorimetric assay using
OPD (o-phenylenediamine dihydrochloride; Sigma-Aldrich) in coded picture
buffer (CPB) solution, that is, a 10-mg OPD tablet in 25 mL of citrate-phosphate
buffer (25mM citric acid, 5 mM Na2HPO4) with 10L of 30% H2O2. The
highest dilution showing an OD450	 0.1 was recorded as the titer. Antibody titer
data were plotted on log scales.
Cross-presentation of Gag to HIV-primed human CD8 T cells
PBMCs from HIV-infected donors were labeled with 1M CFSE and 106
cells plated in 96-deep well plates in 500 L of RPMI with 5% human
serum. PBMCs were cultured 7 days with no Gag antigen (negative control)
or with HIV Gag peptides at 2 g/mL or MG38.2-Gag p24, 3D6-p24,
3G9-p24, and control Ig-p24 at 1 g/mL. To directly assess the function of
DCs in presenting the Gag fusion mAbs, we used MoDCs in parallel to the
PBMC assay described above. Immature DCs at day 5 of monocyte culture
in GM-CSF and IL-4 were collected and pulsed overnight with medium,
p24 peptides (2 g/mL), or MG38.2-p24, 3D6-p24, 3G9-p24, and control
Ig-p24 at 1 g/mL. The antigen-pulsed MoDCs were matured by adding
-irradiated CD40L-expressing cells (kindly provided by J. Banchereau,
Dallas, TX) at a ratio of 1:5 (CD40L:DC) for 48 hours. CD40 ligation
enhances cross-presentation by DCs.22 Syngeneic CD14 cells were
thawed, rested for 2 hours at 37°C before CFSE labeling, plated in 48-well
plates at 1.5-2  106/mL, and cultured 6 days with the antigen-pulsed
mature MoDCs at a DC:T ratio of 1:30. After 6-7 days of culture, all
samples were restimulated 8 hours 
 p24 peptides (2 g/mL) with
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0.5 g/mL anti-CD28 and CD49d (clones L293 and L25; BD Biosciences).
Brefeldin A, at 10 g/mL, was added for the last 6 hours. The cells were
fixed, permeabilized, and stained with perCP-anti-CD3, APC-anti-CD8,
and PE-anti-IFN- or its respective isotype control (all from BD Bio-
science). Cells were analyzed with a BD FACSCalibur, collecting 50 000-
100 000 high CD3 events.
All human subject experiments were approved by The Rockefeller
University Institutional Review Board.
Results
Production of hDEC205/hIgG1Fc fusion protein
To express hDEC205, cDNAs encoding full-length DEC205 pro-
teins from human and mouse were cloned by PCR based on
published sequences.6,19 A V5 epitope tag was inserted into the
N-terminus to detect the expression of recombinant hDEC205
protein or transgene. The cDNAs of V5-tagged hDEC205 (Gen-
Bank accession no. AY682091) and C57BL/6 mDEC205 (Gen-
Bank accession no. AF395445) were used to generate stable CHO
cells expressing cell-surface DEC205. To prepare a secreted form
of DEC205, the full-length extracellular domain of hDEC205
cDNA was fused to a human IgG1 Fc cassette (V5.hDEC205/
hIgG1Fc; GenBank accession no. DQ407610), transfected, and
stably expressed in CHO cells (Figure 1A left) to produce
V5.hDEC205/hIgG1Fc protein of 90% or better purity after protein
A (Figure 1A right). This protein was used to prepare mAbs.
Generation of human anti–human DEC205/CD205 mAbs
Human Ig Tg mice15 were used to generate human anti-hDEC205
mAbs by standard immunization and hybridoma technology. Both
complete/incomplete Freund and RIBI MPL plus TDM adjuvants
resulted in good antibody titers to hDEC205. Spleen cells harvested
at peak titers were fused with murine P3  63Ag8.653 myeloma
cells, cultured in selection media, and hybridoma supernatants
initially screened for human IgG with an isotype-specific sand-
wich ELISA. Human IgG supernatants were assayed for reactiv-
ity to hDEC205 by FACS on CHO/hDEC205 cells and ELISA with
V5.hDEC205/hIgG1Fc-coated plates.
Five selected mAbs, named 3C7, 3D6, 3G9, 5A8, and 5D12, were
further characterized for binding to cell-surface hDEC205. All 5 mAbs
and MG38.2, which is a mouse anti-hDEC205 mAb generated previ-
ously,19,20 bound to CHO/hDEC205 cells, but not to CHO/mDEC205
cells, while NLDC145 anti-mDEC205 mAb bound only to CHO/
mDEC205 cells (Figure 1B). When new anti-hDEC205 mAbs were
used to stain human MoDCs, binding was observed, and, as expected,
mature hMoDCs expressed higher levels of hDEC205 (Figure 1C). The
5 new anti-hDEC205 mAbs exhibited stronger binding to hDEC205
than the earlier MG38.2 mAb. 3D6 and 3G9 mAbs showed the highest
binding affinities to hDEC205 on both CHO/hDEC205 cells and
Figure 1. Generation of human anti-hDEC205 monoclonal antibodies. (A) Expression of soluble human DEC205-human IgG1 Fc (V5.hDEC205/hIgG1Fc) fusion protein.
Left: CHO cells, transfected with control plasmid (lane 1) and V5.hDEC205/hIgG1Fc (lane 2), were lysed and analyzed by Western blotting with anti-V5 antibody. Right: purified
human IgG1 Fc alone (lane 1) or V5.hDEC205/hIgG1Fc fusion proteins (lane 2) produced by transfected CHO cells were analyzed on SDS-PAGE and stained by Coomassie
blue. (B) FACS labeling of CHO/hDEC205 and CHO/mDEC205 cells and (C) human MoDCs stained at 1 g/mL with human anti-hDEC205 mAbs, as well as the previously
described NLDC145 rat anti-mDEC205 and MG38.2 mouse anti-hDEC205. The MoDCs were treated with/without LPS (100 ng/mL) to generate mature and immature DCs. (D) Lysates
from CHO/Neo (lane 1), CHO/hDEC205 (lane 2), and CHO/mDEC205 (lane 3) cells were analyzed by Western blotting with mAbs 3G9 anti-hDEC205, NLDC145 anti-mDEC205, and
anti-actin. (E) A series of deletion constructs in the extracellular domain of human DEC205 were generated (left, underlines), each with a FLAG tag, and each FLAG-tagged deletion
construct was expressed in 293T cells. To map the 3G9 epitope on DEC205, each cell lysate was analyzed by Western blotting with mAbs 3G9 and L5 anti-FLAG.
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hMoDCs (Figure 1B-C). In addition, the binding affinity and binding
kinetics of human anti-hDEC205 mAbs were examined by Biacore SPR
analysis, where 3D6, 3G9, and 5D12 mAbs exhibited the highest
affinity to hDEC205 protein (Table 1). One of these new anti-hDEC205
mAbs, 3G9, also detected hDEC205 protein expressed in CHO/
hDEC205 cells by Western blotting (Figure 1D), verifying that the mAb
detected the appropriate antigen when expressed on the cell surface
(Figure 1B-C) and by immunoblotting (Figure 1D). When blotting was
used to determine the subdomain of hDEC205 protein reactive to 3G9,
the epitope was in carbohydrate recognition domains (CRDs) 1 and
2 (CRD1/2; Figure 1E). As a control, we used either a nonbinding
human IgG1 or 3G9 mAb with mutated complementarity determining
region (CDR) sequences. The new human anti-hDEC205 mAbs were
then tested for reactivity with hDEC205 in vivo.
Generation of hDEC205 Tg mice
To establish the in vivo targeting activity of human anti-hDEC205
mAbs, we generated Tg mice expressing hDEC205 in mouse DCs.
To do so, we used the promoter of the CD11c integrin  subunit,
which is expressed at high levels on most DC subsets in mice.
Full-length hDEC205 cDNA linked to a previously described
5.8-kb fragment of mouse CD11c promoter23 (CD11c-hDEC205;
Figure 2A) was integrated into the genome of C57BL/6 mice.
Because the sequences of human and mouse DEC205 cDNAs are
highly homologous, a set of PCR primers was designed to
discriminate hDEC205 cDNA transgene from the mDEC205 gene,
which contains introns (Figure 2B). Using this primer pair, we
identified several founders expressing the hDEC205 transgene
through germ-line transmission to the next generation (Figure 2C).
Because 3G9 mAb showed the strongest binding to hDEC205 in
FACS and Western blot analyses (Figure 1B-E), we used 3G9 to
detect hDEC205 in tissues of the founder lines (Figure 2C). In the
initial screen by FACS, the no. 49 line exhibited the highest
expression of hDEC205 in spleen and lymph nodes (data not
shown). These results were confirmed by immunolabeling of tissue
sections, such as in lymph nodes of hDEC205 Tg no. 49, but not
wild-type, mice, hDEC205 was localized to dendritic profiles in the
T-cell areas where DCs typically reside (Figure 2D).
To confirm hDEC205 expression on DCs from CD11c-
hDEC205 Tg #49 mice, lymphoid cells were surface stained with 3G9
mAb. In the spleen, CD8 and CD8 classical DCs (cDCs) expressed
hDEC205, but plasmacytoid DCs (PDCs) did not (Figure 2E), while in
lymph nodes, both cDCs and migratory DCs selectively expressed
hDEC205 (Figure 2F). CD11c-hDEC205 Tg no. 49 mice were chosen
to test anti-hDEC205 mAbs for DC targeting.
Targeting of 3G9 mAb to DCs in vivo
To assess the targeting of 3G9 mAb to DCs in vivo, 30 g of Alexa
647–labeled 3G9 or control mAb was injected intraperitonally into
wild-type and CD11c-hDEC205 Tg mice. Neither of the injected
mAbs was detectable in wild-type mice, but in hDEC205 Tg mice,
the injected 3G9 selectively labeled splenic cDCs, while the control
human IgG1 did not label any targets (Figure 3). Thus, 3G9 mAb
targets to hDEC205 on DCs in vivo.
Production of anti-hDEC205-p24 fusion mAbs
To evaluate the capacity of hDEC205 receptor on DCs to process
and present antigens, 3D6 and 3G9 cDNAs were cloned and
engineered to generate hybrid mAbs fused with HIV Gag p24
(Figure 4A). A control human IgG1 mAb Gag p24 fusion mAb was
also generated by mutation of 3G9 parental CDR sequences.
Following expression from mammalian cells and purification by
protein A, the integrity and specificity of the Gag p24 fusion mAbs
were confirmed by Coomassie stains, Western blots (Figure 4B),
and FACS analyses with CHO/hDEC205 cells (Figure 4C). Next,
we stained normal human spleen sections with 3G9-p24 fusion
mAb. 3G9-p24 and MG38.2, a mouse anti-hDEC205, colabeled
hDEC205 DCs in T areas of the human spleen (Figure 4D).
Therefore, the human anti-hDEC205-HIV Gag p24 fusion mAb
vaccines were ready for testing in mice.
Antigens targeted to hDEC205 are efficiently presented to
CD4 T cells in vivo
The HIV Gag p24-conjugated anti-hDEC205 fusion mAbs with
adjuvant induced high frequencies of IFN- (and IL-2; data not
shown) producing CD4 T cells in hDEC205 Tg mice, compared
with control Ig-p24 immunization (Figure 5A). Pools 1 and 4 from
the Gag peptide library were recognized by the CD4 T cells
(Figure 5A), which is in accordance with our previous immunizations
with anti-mDEC205 Gag mAb.10 In 3 experiments of the primary
response to fusion mAb with poly IC and anti-CD40 as adjuvants,
3G9-p24 induced significantly more IFN- (and IL-2; data not shown)
producing CD4T cells than 3D6-p24 and many more T cells relative to
nontargeted control Ig-p24 mAb (Figure 5A).
To extend the study to an adjuvant with a good safety profile in
human subjects, we used poly ICLC (poly IC complexed with
poly-L-lysine and carboxymethylcellulose) only to prime and boost
mice 1 month apart with 3G9-HIV Gag p24 and 3G9-SIV Gag p27.
The combination of targeted vaccine plus poly ICLC was immuno-
genic in hDEC205 Tg mice (Figure 5B). We also immunized with
3G9-SIV Gag p41 to test if epitopes from both SIV Gag p17 and
SIV Gag p27 regions were immunogenic, and this was the case
(Figure 5C). To evaluate the quality of the T-cell response, we
showed that the T cells were capable of antigen-specific prolifera-
tive activity (Figure 5D). Thus, high frequencies of CD4 T cells
with potentially valuable properties, such as breadth and prolifera-
tive capacity, can be primed with anti-hDEC205 Gag fusion mAbs.
Induction of humoral responses to anti-hDEC205 antibodies
in vivo
To examine humoral responses in hDEC205 Tg mice, 10 g of
3D6, 3G9, or control human IgG1 mAbs were injected intraperito-
neally with adjuvant. One immunization of hDEC205 Tg mice with
Table 1. Affinity and kinetic parameters (with background subtracted)
mAb ID ka, 1/Ms kd, 1/s KA, 1/M KD, M RMax, RU
5A8 3.6  105 2.0  104 2.1  109 1.5  109 172
3C7 1.7  105 7.6  104 5.2  108 5.6  109 133
3D6 1.8  106 1.2  104 1.5  1010 8.0  1011 294
5D12 5.4  105 3.2  104 2.0  109 7.0  1010 272
3G9 9.0  105 1.9  104 4.7  109 2.4  1010 268
For each antibody, the figures shown are the mean of 2 separate series of experiments, using separately prepared sensor chips in each case, where: ka indicates kinetics
of association; kd, kinetics of dissociation; KD, dissociation rate constant (measure of affinity); KA, association rate constant; and RMax, maximum SPR response signal.
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anti-hDEC205 mAbs 3D6 and 3G9 was sufficient to induce high
IgG antibodies against human IgG1 (Figure 6). These antibodies
against human anti-hDEC205 mAbs included a spectrum of all IgG
subclasses (ie, IgG1, IgG2b, IgG2c, and IgG3). There was no
significant difference in total IgG titers between hDEC205 Tg mice
immunized with 3D6 and 3G9 (Figure 6A); however, the mice
immunized with 3D6 had slightly higher IgG2c and IgG3 titers
than those immunized with 3G9 (Figures 6C,E). High antibody
titers against anti-hDEC205 mAbs were induced with an additional
round of immunization in the absence of adjuvant (Figure 6). In the
same experiment, control human IgG1 mAb generated no detect-
able humoral IgG responses in hDEC205 Tg mice (Figure 6),
indicating the greatly enhanced humoral responses to anti-3D6 and
-3G9 mAb targeting.
Cross-presentation of human anti-hDEC205 HIV Gag to Gag
primed T cells
To assess the capacity of the 3D6 and 3G9 mAbs to mediate
cross-presentation, we studied HIV-primed CD8 T cells from
HIV-infected individuals as previously described,11 since we were
unable to prime large numbers of CD8 T cells to HIV Gag in
Figure 2. Generation of hDEC205 transgenic mice. (A) Schematic of a linearized CD11c promoter-hDEC205 transgene. (B) PCR genotyping strategy for hDEC205 Tg mice,
where a set of primers was selected for conserved sequences between mouse and human DEC205. The shorter (165 bp) PCR amplicon is generated from the hDEC205
intronless transgene and the longer (293 bp) from the mouse DEC205 gene. Arrows indicate the positions of F (forward) and R (reverse) primers. (C) A representative gel of
5 hDEC205 Tg founders after PCR of genomic DNA from newborn Tg mouse tails. M is for a lane loaded with molecular weight markers, and bold numbers (17, 42, 43, 44, and
49) indicate the lanes with samples from founder mice carrying the transgene. (D) Localization of hDEC205 in lymph nodes of hDEC205 Tg no. 49 and wild-type mice was
visualized by immunohistochemistry. Acetone-fixed cryostat sections of subcutaneous lymph nodes were stained with 3G9 mAb, followed by secondary PE-conjugated
antihuman IgG, and FITC-anti-B220 to discriminate B and T areas. Images were taken 200 magnification, but the region with the asterisk (*) is magnified 400 on the right
using a Molecular Devices OlympusAX70 deconvolution microscope (Olympus) running METAMORPH Meta Imaging 3.0 (Universal Imaging Corporaration). (E) Expression of
hDEC205 in the spleen of wild-type and hDEC205 Tg no. 49 mice. Lymphocyte lineage (CD3, CD19, and DX5) negative cells were surface stained with antibodies for hDEC205
(3G9-Alexa647), CD11c, CD8, and PDCA1 to monitor hDEC205 expression in PDCs (PDCA1), and cDCs (CD11c and CD8 or CD8). (F) Skin-draining lymph node cell
suspension from wild-type and hDEC205 Tg no. 49 mice were stained with mAbs for hDEC205 (3G9-A647), CD11c, and MHC II to detect hDEC205 in migratory DCs and
cDCs. In histograms, blue is for wild-type (WT) and red for hDEC205 Tg mice (Tg; E-F).
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hDEC205 Tg mice in the C57BL/6 background. We compared the
human-Gag p24 fusion mAbs to mouse MG38.2 anti-hDEC205-
p24 and nonbinding control Ig-p24. Either whole PBMCs (Figure
7A) or mixtures of MoDC and T cells (Figure 7B) were used as
previously described.11 Anti-hDEC205 mAbs at just 1 g/mL
induced T-cell proliferation and IFN- production from primed
CD8 T cells, comparably to cells expanded with a pool of
50 peptides spanning the Gag p24 sequence (Figure 7). Thus, the
human anti-hDEC205 mAbs mediate cross presentation.
Discussion
Protein vaccines offer considerable potential relative to vector-
delivered vaccines in terms of reduced expense of production, ease
of transport and storage, and capacity to repeatedly immunize
without the obstacle of vector immunity. To render protein vaccines
immunogenic, we have previously shown the value of targeting to
Figure 3. Targeting of 3G9 to DCs in vivo. Wild-type and hDEC205 Tg mice were injected intraperitoneally with Alexa 647–labeled 3G9 or human IgG1 isotype (30 g per
mouse). Twelve hours later, lymphocyte lineage-negative (LIN) splenic cell suspensions were stained with the indicated antibodies. In the histograms, blue is for wild-type
(WT) and red for hDEC205 Tg mice (Tg).
Figure 4. Expression and binding of hybrid anti-hDEC205-HIV Gag p24 fusion mAbs. (A) Schematic view of engineered mAb fused with HIV Gag p24. (B) Purified
anti-hDEC205 mAbs 3D6 and 3G9 and their p24-fused hybrid mAbs were separated on 10% SDS-PAGE and stained with Coomassie blue (left) and blotted with anti-HIV Gag
p24 antibodies (right). (C) Binding of hybrid mAbs to CHO/hDEC205, CHO/mDEC205, and control CHO/Neo cells using graded doses of purified recombinant p24-fused
mAbs, followed by anti-hIgG-PE. (D) Detection of hDEC205 in normal human spleen sections after costaining with biotinylated 3G9-p24 (Alexa 555, red), MG38.2 mouse
anti-hDEC205 (Alexa 488, green), and anti-hCD3 (APC, blue) to mark the T-cell areas. Images were taken 200 magnification using a Molecular Devices OlympusAX70
deconvolution microscope running METAMORPH Meta Imaging 3.0
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receptors on DCs along with coadministration of adjuvants that
render DCs immunostimulatory. In our studies, we have empha-
sized the DEC205 receptor for targeting and poly IC as an adjuvant.
To bring this potentially protective strategy into the clinic, it
would help to have fully human anti-hDEC205 fusion mAbs.
Human mAbs to hDEC205 proved feasible to produce using
human DEC205 extracellular domain to immunize mice carrying
human, not mouse, Ig genes. We selected 2 mAbs, 3G9 and 3D6,
for study because they both bound to human and rhesus DEC205 at
high affinity. To carry out in vivo immunization experiments, we
Figure 5. hDEC205 targeting with adjuvant induces Gag-specific CD4 T-cell responses. (A) hDEC205 Tg mice were injected intraperitonally with 10 g of purified
3G9-HIV Gag p24, 3D6-p24, or control Ig-p24 fusion mAbs along with 50 g of poly IC and 25 g of anti-CD40 mAb. After 2 weeks, splenic T-cell responses to pools of p24
peptides were analyzed. FACS plots from a representative experiment and histograms from 3 independent experiments are shown in percentiles of CD3, IFN-–producing
CD4 T cells; similar results were obtained for IL-2–producing cells (not shown). Asterisks for statistically significant changes (*P  .05, **P  .01). (B) As in panel A, but
prime-boost immunizations with 3G9-HIV Gag p24 (left, in blue) or 3G9-SIV Gag p27 (right, in red), plus only poly ICLC as an adjuvant. (C) SIV Gag p41 was the immunizing
antigen to test responses to p17 and p27 regions of Gag. (D) As in panel A, showing IFN-–producing T cells after immunization with 3G9-HIV Gag p24, but not control
anti-human DC-SIGN-p24 (left), and also specific proliferation (CFSE dilution) to HIV Gag p24, not HIV Gag p17 peptides (right). hDEC205 Tg in C57BL/6 background (A-C)
and crossed with B10.BR (D).
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also developed a Tg mouse expressing full-length hDEC205 in
DCs under control of the CD11c promoter and assessed the
immunological responses of hDEC205 targeting in vivo. These
mice express hDEC205 exclusively in CD11chigh DCs, although the
frequency of DEC205 expressing DCs is not 100% and varies
among individual Tg mice. Targeting of anti-hDEC205 mAb
selectively labeled DCs, and these DCs were found in the T-cell
areas of the lymph nodes.
We then found that these Tg mice developed strong CD4 T-cell
responses to hDEC205-targeted HIV and SIV Gag proteins, but not
control Ig-targeted Gag. The T-cell responses showed 2 valuable
features: breadth or capacity to recognize several different Gag
peptides and proliferative capacity. In prior research,13 we found
that the T-cell responses to DEC205-targeted antigen in mice are of
the Th1 and not Th2 or Th17 types. We have been verifying this in
ongoing studies in rhesus macaques, where we used the 3G9-HIV
gag p24 fusion mAb along with poly IC to immunize nonhuman
primates. However, Gag-specific CD8 T cells were not detected in
our immunized C57BL/6 mice, which are not known to present
HIV Gag on MHC class I.10 To verify that the new anti-hDEC205
mAbs could enhance cross-presentation, we carried out experi-
ments with CD8 T cells from HIV-infected individuals. We had
shown previously that mouse antihuman DEC-targeted gag p24
was reliably cross-presented to human CD8 T cells. Here, we
verified that human 3G9 and 3D6 anti-DEC205 greatly enhanced
cross-presentation relative to control fusion mAbs, and were as
active as pools of Gag peptides to load antigen into DCs. We did
not assess the behavior of regulatory Foxp3 T cells in the current
paper, because, in a prior study, we showed that the use of poly IC
as an adjuvant blocks the induction of Treg by DEC205-targeted
antigen.24
To assess B-cell responses, we followed antibody formation to
the human IgG following 3G9 and 3D6 immunization. The new
targeting mAbs, but not nontargeting control, elicited high titers of
anti-human IgG. These B- and T-cell findings propend feasibility to
use protein vaccines to induce immunity to clinically relevant
antigens as long as these are delivered efficiently to DCs together
with appropriate adjuvants. Since DEC205 targeting enhances the
immunogenicity of protein vaccines, which offer potential advan-
tages with respect to ease and low costs of production, and ability
to be administered repeatedly, we propose to test human DEC-
targeted protein antigens as stand-alone vaccines and in combina-
tion with other approaches, such as recombinant viral vectors.
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